World-Class CDMO Services in India for Russia
CDMO in India for Russia & CIS — Built for Supply Continuity
Shilpa Pharma delivers reliable, compliant, end-to-end CDMO services from India to pharmaceutical and biotech companies across Russia and the CIS.
As global supply chains have tightened, India has remained a dependable, large-scale source of regulated pharmaceutical manufacturing, and Shilpa Pharma turns that reliability into a single, accountable partnership, from molecule to market.
Operating under a broad stack of international approvals, including US FDA, EU GMP and WHO-GMP, and with Raichur API operations that have been inspected against Russian GMP requirements, we help Russian partners accelerate development, support EAEU registration, and secure uninterrupted, regulated-grade supply.
Our CDMO Specialties
Our state-of-the-art API facility handles complex, high-value chemistries that only a limited number of manufacturers worldwide can deliver:
- High pressure reaction with Pd/Ru/Rd etc., Hydrogenation
- Brominating/Chlorination
- Cyanation
- Electro-chemical reactions
- Asymmetric synthesis
- Cryogenic reactions (up to -90°C)
- Boron Chemistry
- Hydrogenation including asymmetric capabilities
- Butyl Lithium Reaction
- Chiral Synthesis
- Cyclopropane Chemistry
- Grignard Reaction
- Indole Chemistry
- Nucleoside Chemistry
- Purine Chemistry
- Pyridine Chemistry
- Pyrimidine Chemistry
- Steroid Chemistry
- Oxidation and reduction reactions
- Pressure reactions
- Enzymatic reactions
- Use of phase transfer catalyst
- Cytotoxic (Onco) products Can handle with isolators.
Have Questions? We’re Here to Help
Happy Customers
Projects Successfully Completed
Established
PhD Experts Driving R&D Excellence
Team Size
World-Class API Manufacturing Sites
Global Audits Successfully Completed
Comprehensive CDMO Service Offerings
Shilpa Pharma Globally Accredited CDMO Partner
Shilpa Pharma’s facilities operate under multiple global regulatory certifications, reflecting our commitment to quality and compliance. This global compliance framework makes Shilpa Pharma a preferred CDMO partner for Russian companies seeking regulated-grade manufacturing capabilities from India.
Why Shilpa Pharma is Your Trusted CDMO Partner for Russian Markets
As a globally accredited CDMO based in India, Shilpa Pharma supports Russian and CIS pharmaceutical companies with end-to-end, compliant, and cost-effective manufacturing solutions.
End-to-End CDMO Solutions
From route scouting to GMP manufacturing, we cover every stage of drug development.
State-of-the-Art R&D
Advanced laboratories for formulation, biologics, and peptide research.
Global Quality Standards
GMP-compliant facilities ensuring regulatory-ready production.
Advanced Manufacturing Capabilities
High-potent APIs, continuous flow chemistry, and scalable processes.
Sustainable & Compliant Operations
Environmentally responsible practices with stringent safety protocols.
Trusted by Pharma Innovators
Reliable partnerships delivering complex projects on time and within budget.
Contract Manufacturing: India to Russia
Shilpa Pharma is a world-class contract manufacturing organisation in India, delivering precision manufacturing, consistent reliability, and uncompromised regulatory compliance for Russian and CIS partners. From raw-material sourcing to final packaging, every process is managed with transparency, robust documentation, and strict quality control, ensuring exceptional batch-to-batch consistency and dependable, on-time delivery.
Our facilities enable the production of complex APIs, advanced oncology compounds, HPAPIs, and specialty intermediates that only a limited number of manufacturers globally can deliver.
- Precision & Compliance: Manufacturing under stringent international and EAEU-aligned regulatory guidelines.
- Advanced Facilities: Ten manufacturing blocks (five oncology, five non-oncology) with large reactor capacity for high-value, niche products.
- End-to-End Manufacturing: Seamless execution from technology transfer to commercial production.
CONTRACT DEVELOPMENT
Shilpa Pharma’s contract development services support Russian pharmaceutical companies with robust, compliant, and scalable development aligned to global and EAEU quality standards. Leveraging advanced R&D and GMP-certified facilities in India, we assist partners at every stage, from route scouting and process optimisation to formulation development and pilot-scale manufacturing. Our strength lies in complex, rare, and high-value molecules, including oncology compounds and specialty intermediates.
Questions & Answers
Our FAQ's
Everything You Need to Know About API Manufacturing in India at Shilpa Pharma
What CDMO services does Shilpa Pharma provide to Russian pharmaceutical companies?
Shilpa Pharma offers end-to-end CDMO services including custom development, API and formulation manufacturing, process optimization, analytical support, and large-scale production specifically tailored for the Russian market.
Is Shilpa Pharma compliant with global regulatory standards?
 Yes. Our facilities hold certifications from USFDA, EU GMP, PMDA, and other major global regulatory bodies, ensuring international compliance for products intended for Russia and beyond.
Why partner with a CDMO in India for Russia?
Partnering with an India-based CDMO like Shilpa Pharma combines cost-efficiency, advanced technical capabilities, strong regulatory compliance, and reliable supply—ideal for Russian pharma and biotech companies.
Can Shilpa Pharma handle complex APIs for Russian partners?
Yes. We specialize in complex APIs, HPAPIs, oncology compounds, specialty intermediates, peptides, and high-potency manufacturing with advanced quality control and documentation.
Does Shilpa Pharma support technology transfer for Russian projects?
Absolutely. Our experienced teams ensure smooth technology transfer, scale-up support, and regulatory-ready processes optimized for Russian regulatory expectations.
